Overactive Bladder: Antimuscarinics and the Anticholinergic Burden
An overactive bladder is a bladder that will not wait. It squeezes when it should be filling quietly, and the patient is dragged to the toilet by an urgency they cannot argue with — day and night. The drugs that calm it are among the oldest and most reliable in urology, and they work by a beautifully simple idea: turn down the nerve signal that tells the bladder muscle to contract. But the same signal runs the salivary glands, the gut, the pupil and — crucially — the brain. So the story of these drugs is really the story of a trade-off: quieter bladder, drier mouth, foggier mind. Getting that balance right, especially in older patients, is the whole clinical craft.
A 74-year-old woman comes in exhausted. For a year she has been woken three or four times a night by a sudden, urgent need to pass water; twice she has not reached the toilet in time. There is no burning, no blood, and her urine is clear on testing — this is not infection. She has already cut back on tea and stopped drinking after supper on her GP's advice, with only partial help. She is started on an antimuscarinic to quieten the bladder muscle. Two weeks later the urgency is better — but her mouth is so dry she wakes to sip water, and her long-standing constipation has worsened. Her daughter, quietly, mentions she seems a little more muddled. In this one patient sits the entire balance of the class: real relief for a miserable symptom, bought with a side-effect bill that has to be watched, particularly in an older brain.
First, the bladder that contracts when it shouldn't
Overactive bladder is a storage problem, not a plumbing blockage. Overactive bladder (OAB) is a symptom syndrome: urinary urgency, usually with frequency and nocturia, with or without urge incontinence, once infection and other causes are excluded. The underlying fault is a detrusor — the smooth muscle wall of the bladder — that contracts involuntarily during filling, when it should sit quietly and let the bladder store. The Foundations chapter maps the two phases in full: in storage, the sympathetic system relaxes the detrusor and the internal sphincter stays shut; in voiding, the parasympathetic nerves fire and the detrusor contracts to empty. In OAB the storage phase is sabotaged by premature detrusor contractions, and the brain reads each one as a desperate, unignorable signal to void.
Behaviour before drugs — always
No responsible prescription for OAB begins with a tablet. Conservative and behavioural therapy is genuinely first-line and, in many patients, enough. Bladder training (scheduled, gradually lengthening voiding intervals to "re-teach" the bladder to hold), fluid advice (avoiding both dehydration and over-drinking), and reducing bladder irritants — caffeine, alcohol, fizzy drinks — all reduce urgency. Weight loss helps, and treating constipation matters because a loaded rectum aggravates an irritable bladder. For stress or mixed incontinence, supervised pelvic floor muscle training is the evidence-based cornerstone. Drugs are added when these measures fall short — not instead of them. Antimuscarinics work best layered on top of ongoing bladder training, not as a substitute for it.
The mechanism: block the M3 brake pedal
The detrusor contracts because acetylcholine tells it to. Silence that message and the muscle settles. Parasympathetic nerves release acetylcholine onto the detrusor, and the receptor that actually drives contraction is the M3 muscarinic receptor. (M2 receptors outnumber M3 on the bladder, but it is M3 that does the mechanical work of squeezing.) Antimuscarinics are competitive antagonists at these receptors: they block acetylcholine from binding, so the involuntary contractions of filling are damped down. The bladder relaxes, holds more, and the storm of urgency signals quietens — the effective bladder capacity rises and the patient can wait. This is applied pharmacology straight from the Autonomic Nervous System chapter: the same muscarinic-blockade principle behind a dry mouth from an antihistamine or a dilated pupil from atropine, aimed here deliberately at the bladder. Because the target receptor sits all over the body, though, the same block that quietens the detrusor inevitably reaches everywhere else muscarinic receptors live.
Think of the bladder as a room with an over-sensitive smoke alarm that shrieks at every wisp of steam from the kettle. An antimuscarinic doesn't fix the kettle — it turns down the alarm's sensitivity so it only sounds for a real fire. The relief is immediate. The catch is that it's the same brand of alarm wired into every other room of the house — the kitchen (gut), the bathroom (salivary glands), the study (the brain) — so turning down the sensitivity dims them all a little. Turn it down too far in the study, and an older occupant starts missing things they used to notice.
The agents: from oldest-and-dirtiest to bladder-selective
The class spans a spectrum defined mostly by selectivity and side-effect load. Oxybutynin is the oldest and cheapest; it is effective but the most anticholinergic, with the worst dry mouth and the greatest central penetration — which is why the transdermal patch (or gel) exists, delivering drug while bypassing the first-pass metabolite that drives much of the dry mouth. Tolterodine is somewhat better tolerated. Solifenacin and darifenacin are more bladder-selective (relatively M3-preferring), aiming to spare some off-target effects. Fesoterodine is a prodrug related to tolterodine. Trospium stands apart: it is a quaternary amine, so it is charged and crosses the blood–brain barrier poorly — a useful property when the priority is protecting an older brain. None of these is dramatically more effective than another; the real choice is driven by tolerability, central risk, and cost.
Oxybutynin — oldest, cheapest, most anticholinergic; immediate-release worst for dry mouth and CNS effects, transdermal patch far gentler. Tolterodine and fesoterodine (its prodrug) — moderate tolerability. Solifenacin and darifenacin — more M3/bladder-selective. Trospium — quaternary amine, minimal brain penetration, a rational pick in the frail elderly or those with cognitive concern. A practical rule of thumb: in an older patient, immediate-release oxybutynin is usually the wrong first choice precisely because of its central load.
- OAB = urgency ± frequency, nocturia and urge incontinence, driven by involuntary detrusor contractions during filling.
- Behavioural therapy (bladder training, fluid/caffeine advice, pelvic floor) is first-line — always before or alongside drugs.
- Antimuscarinics block the detrusor M3 receptor, damping contractions and raising bladder capacity/storage.
- Agents differ mainly by selectivity and side-effect load, not by how well they work.
- Oxybutynin = most anticholinergic (patch is gentler); trospium = quaternary, spares the brain; solifenacin/darifenacin = more M3-selective.
The dominant issue: the anticholinergic side effects
"Can't see, can't pee, can't spit, can't shit" — the classic anticholinergic quartet, and the reason most patients stop. Because M-receptors sit everywhere, blocking them produces a predictable, textbook syndrome. Dry mouth is the commonest and the leading reason patients abandon treatment — adherence to this class is genuinely poor. Constipation follows (blocked gut muscarinic drive slows the bowel), then blurred vision and dry eyes (loss of accommodation and tear production). There is a paradox worth naming: although these drugs treat a urinary problem, by relaxing the detrusor too far they can cause incomplete emptying and even urinary retention — so "can't pee" sits, ironically, alongside the very symptom being treated. Other predictable effects are tachycardia (M2 blockade in the heart) and reduced sweating, which can cause overheating in hot weather. Most of these are dose-related and often ease over the first weeks, but for many patients the dry mouth alone is the deal-breaker.
The central cost — and the dementia signal
The effects that matter most are the ones inside the skull. Muscarinic transmission is central to memory and cognition, so drugs that cross the blood–brain barrier can cause confusion, cognitive impairment and even delirium — a risk that rises steeply in the elderly, whose brains are more permeable and already lower on acetylcholine. This is one of the strongest arguments in geriatric prescribing: think in terms of total anticholinergic burden — the summed load of every drug a patient takes with anticholinergic action (bladder drugs, sedating antihistamines, tricyclic antidepressants, some antipsychotics). The more agents stacked, the greater the confusion, falls and functional decline. Beyond acute confusion, observational studies have linked cumulative, long-term anticholinergic exposure — bladder antimuscarinics prominently among them — to a higher subsequent risk of dementia. The signal is an association, not proven causation, but it has reshaped practice: in older patients, minimise the total anticholinergic load, prefer bladder-selective or peripherally-restricted agents (trospium, or the transdermal route), keep the dose and duration to the minimum that helps, and actively reconsider whether the drug is still earning its place. Where cognition is the overriding concern, the beta-3 agonist alternative — which sidesteps muscarinic blockade entirely — often becomes the more rational choice. These central effects tie directly into the Central Nervous System chapter on the cholinergic basis of cognition.
The single most useful reflex when you see an antimuscarinic prescribed for an older patient: total the anticholinergic burden across the whole medication list, not just this one drug. A modest bladder antimuscarinic added on top of a sedating antihistamine and an amitriptyline is not a modest dose — it is a third anticholinergic straw on a loaded camel, and the confusion or fall that follows is entirely predictable. Deprescribing a competing anticholinergic often helps the patient more than any tweak to the bladder drug itself.
When not to reach for them
Several contraindications flow straight from the mechanism. Narrow-angle (angle-closure) glaucoma is the classic one: muscarinic blockade dilates the pupil, which can crowd the drainage angle and precipitate an acute rise in intraocular pressure — this links to the Ophthalmology chapter on angle-closure. Significant bladder outlet obstruction or existing urinary retention is another: relaxing an already poorly-emptying detrusor invites frank retention (a particular caution in men with prostatic enlargement — see the BPH pathway). Severe gastrointestinal disease matters too — gut atony, significant constipation, and conditions like toxic megacolon or myasthenia gravis (where cholinergic transmission is already compromised) are cautions or contraindications. And in the frail elderly with cognitive impairment, the central-effect risk itself acts as a relative contraindication. Efficacy, meanwhile, should be framed honestly: antimuscarinics typically deliver a modest reduction — perhaps one or two fewer urgency or incontinence episodes a day over placebo — which, combined with the side effects, is exactly why adherence at a year is low and why realistic counselling matters.
- Classic anticholinergic burden: dry mouth (commonest, drives non-adherence), constipation, blurred vision, tachycardia, reduced sweating.
- Paradoxical urinary retention: over-relaxing the detrusor can worsen emptying — the drug's own target symptom.
- Central effects (confusion, delirium, cognitive decline) matter most in the elderly; think total anticholinergic burden.
- Long-term cumulative use carries an association with higher dementia risk — minimise load, prefer selective/peripheral agents.
- Avoid in narrow-angle glaucoma, significant outlet obstruction/retention, and severe GI disease (e.g. toxic megacolon, myasthenia).
- Efficacy is modest; adherence at a year is low — counsel realistically and pair with behavioural therapy.
- Reaching for immediate-release oxybutynin first in a frail older patient — its high central penetration risks confusion and delirium; a bladder-selective or quaternary agent (trospium), or the patch, is safer.
- Prescribing an antimuscarinic in narrow-angle glaucoma — pupillary dilatation can precipitate acute angle-closure and a sight-threatening pressure spike.
- Judging the drug on this prescription alone. Ignoring the patient's other anticholinergics (sedating antihistamines, TCAs) underestimates the true burden and the resulting fall/confusion risk.
An 80-year-old man with mild cognitive impairment and benign prostatic enlargement has troublesome urgency after failing bladder training. Which drug choice is most appropriate?
- OAB (urgency, frequency, nocturia, urge incontinence) is driven by an involuntary detrusor; behavioural therapy is first-line, drugs are added on top.
- Antimuscarinics block the detrusor M3 receptor to damp contractions and increase storage; agents (oxybutynin, tolterodine, solifenacin, darifenacin, fesoterodine, trospium) differ by selectivity and side-effect load, not efficacy.
- The dominant problem is the anticholinergic burden — dry mouth, constipation, blurred vision, paradoxical retention, and central confusion/cognitive decline, worst in the elderly, with an association to dementia risk.
- Minimise total load, prefer bladder-selective/peripheral agents (trospium, the patch), avoid in narrow-angle glaucoma, outlet obstruction and severe GI disease, and consider the beta-3 agonist as the anticholinergic-sparing alternative.
- NICE guideline NG123 — Urinary incontinence and pelvic organ prolapse in women: management.
- European Association of Urology (EAU) Guidelines on Non-neurogenic Female/Male Lower Urinary Tract Symptoms.
- Rang & Dale's Pharmacology — Cholinergic transmission and muscarinic antagonists; the urinary tract.
- Katzung's Basic & Clinical Pharmacology — Cholinoceptor-blocking drugs.
- British National Formulary (BNF) — Urinary frequency, enuresis and incontinence; antimuscarinics.
- Coupland CAC, et al. Anticholinergic Drug Exposure and the Risk of Dementia: a nested case-control study. JAMA Internal Medicine.
